Cargando…
驱动基因阳性肺腺癌在靶向治疗中病理类型转化的机制与治疗策略
Patients with lung adenocarcinoma (ADC) who harbor drive gene mutation will inevitably develop drug resistance after receiving targeted therapy. The common mechanisms of drug resistance include secondary mutation of driver gene, change of non-driver gene, histological transformation and epithelial m...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7467985/ https://www.ncbi.nlm.nih.gov/pubmed/32758349 http://dx.doi.org/10.3779/j.issn.1009-3419.2020.102.22 |